Therefore, GAS5 activates the Wnt/β-catenin signaling pathway via the GAS5/miR-221-3p/DKK2 axis and may be used to enhance the sensitivity of breast cancer patients to ADR treatment [53]. This evidence concerns the gene GAS5 and breast carcinoma.